The unclear role of PET–CT in localized radiorecurrent prostate cancer

Competing interests

H.U.A. receives core funding from the UK National Institute of Health Research (NIHR) Imperial Biomedical Research Centre, the Wellcome Trust, the UK NIHR, the UK Medical Research Council, Cancer Research UK, Prostate Cancer UK, The Urology Foundation, the BMA Foundation, Imperial Healthcare Charity, Sonacare, Trod Medical and Sophiris Biocorp; has received a travel allowance from Sonacare; was a paid consultant for Sophiris Biocorp and Sonacare; and is a proctor for Rezūm treatment and cryotherapy for Boston Scientific. The other authors declare no competing interests.

留言 (0)

沒有登入
gif